Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25632150 | 0.92 | DDB1 (0.49) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25634142 | 0.91 | DDB1 (0.54) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25631758 | 0.91 | DDB1 (0.53) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25631762 | 0.88 | DDB1 (0.51) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25631760 | 0.86 | DDB1 (0.50) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL22119507 | 0.85 | DDB1 (0.59) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL31306782 | 0.84 | CYP3A4 (0.48) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL30724065 | 0.83 | CYP11B2 (0.49) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL24480492 | 0.82 | GPR119 (0.66) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL30768912 | 0.81 | CYP11B2 (0.46) | DDB1CRBNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4438603-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-10-02 | — | — | EP | disclosed |
| CN-118234726-A | Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AR, NR5A1, CYP17A1 | DDB1 4432/4885CRBN 743/4885GPR119 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.